These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 27235786)

  • 1. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
    Swedberg MD
    J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current approaches and issues in non-clinical evaluation of abuse and dependence.
    Moser P; Wolinsky T; Castagné V; Duxon M
    J Pharmacol Toxicol Methods; 2011; 63(2):160-7. PubMed ID: 20868759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse liability assessment of neuroprotectants.
    Klein M; Calderon S; Hayes B
    Ann N Y Acad Sci; 1999; 890():515-25. PubMed ID: 10668457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A proactive nonclinical drug abuse and dependence liability assessment strategy: a sponsor perspective.
    Swedberg MD
    Behav Pharmacol; 2013 Sep; 24(5-6):396-402. PubMed ID: 23907375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of substance abuse liability in rodents: self-administration, drug discrimination, and locomotor sensitization.
    Paterson NE
    Curr Protoc Pharmacol; 2012 Sep; Chapter 5():Unit5.62. PubMed ID: 22948849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human abuse liability evaluation of CNS stimulant drugs.
    Romach MK; Schoedel KA; Sellers EM
    Neuropharmacology; 2014 Dec; 87():81-90. PubMed ID: 24793872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties.
    Swedberg MD; Ellgren M; Raboisson P
    J Pharmacol Exp Ther; 2014 Apr; 349(1):155-64. PubMed ID: 24472725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS safety pharmacology: A focus on cognitive functions.
    Hernier AM; Froger-Colléaux C; Castagné V
    J Pharmacol Toxicol Methods; 2016; 81():286-94. PubMed ID: 27071953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of the abuse liability of drugs.
    Johanson CE
    Drug Saf; 1990; 5 Suppl 1():46-57. PubMed ID: 2182063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How good are current approaches to nonclinical evaluation of abuse and dependence?
    Moser P; Wolinsky T; Duxon M; Porsolt RD
    J Pharmacol Exp Ther; 2011 Mar; 336(3):588-95. PubMed ID: 21098089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations.
    Huskinson SL; Naylor JE; Rowlett JK; Freeman KB
    Neuropharmacology; 2014 Dec; 87():66-80. PubMed ID: 24662599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines and methodological reviews concerning drug abuse liability assessment.
    Balster RL; Bigelow GE
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S13-40. PubMed ID: 12759195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects.
    Swedberg MD; Raboisson P
    J Pharmacol Exp Ther; 2014 Aug; 350(2):212-22. PubMed ID: 24876235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse liability assessment of hydrocodone under current draft regulatory guidelines.
    Gauvin DV; McComb M; Code R; Dalton JA; Baird TJ
    J Pharmacol Toxicol Methods; 2015; 75():118-29. PubMed ID: 25969422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States.
    Calderon SN; Klein M
    Neuropharmacology; 2014 Dec; 87():97-103. PubMed ID: 24727212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Abuse Potential Assessment.
    Kallman MJ
    Handb Exp Pharmacol; 2015; 229():115-30. PubMed ID: 26091638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptorome screening for CNS drug discovery.
    Vortherms TA; Roth BL
    IDrugs; 2005 Jun; 8(6):491-6. PubMed ID: 15906196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.